(Total Views: 504)
Posted On: 01/25/2021 9:37:48 AM
Post# of 154140
I'd expect EUA to run the SP to $20+.
Once Covid-19 becomes less prevalent then the revenue stream should be maintained and possibly increased due to "influenza" and bacterial sepsis taking leronlimab's place as a target. Leronlimab's MOA is not specific for a specific germ or virus so should help the host's to survive whatever catastrophe is happening. Adding in revenue from HIV and CA is speculative at this point but looks like it would also contribute to the bottom line in the future also.
I like it!
Quote:
You can't apply a AVG PE to the CYDY COVID play because LL for COVID isn't a stabilized revenue stream. With the vaccine rollout across the globe, there simply won't be a demand for $2B of LL past 21 or 22.”
Read More: https://investorshangout.com/post/view?id=602...z6kZRUZtME
Once Covid-19 becomes less prevalent then the revenue stream should be maintained and possibly increased due to "influenza" and bacterial sepsis taking leronlimab's place as a target. Leronlimab's MOA is not specific for a specific germ or virus so should help the host's to survive whatever catastrophe is happening. Adding in revenue from HIV and CA is speculative at this point but looks like it would also contribute to the bottom line in the future also.
I like it!
(1)
(0)
